Announcement: Spring 2021 Meeting of Oncology Investor Conference Series Moved 1 Day to March 29 - April 1

The Spring 2021 Meeting of the Oncology Investor Conference Series will be hosted virtually Monday, April 29 – Thursday March 1, 2021.  The National Foundation for Cancer for Research is the Platinum Presenting Sponsor.

Over 90 cancer startups, early pre-clinical through clinical, public and private, are expected to present, and over 200+ investors spanning venture, public funds, foundations, family offices, angels, and government grant making entities are expected to attend.


The current keynote and speaker lineup includes:

Dr. Jim Allison, 2018 Nobel Laurate, Partner, Apricity Health, Olga Keith Wiess Distinguished University Chair for Cancer Research, MD Anderson, Director of the Parker Institute for Cancer Research, Executive Director of the Immunotherapy Platform, MD Anderson Cancer
Presenting Apricity Health

Dr. Lynda Chin, CEO, Apricity Health, Founding Chair Department of Genomic Medicine, MD Anderson
Presenting Apricity Health

Moderator, Women’s Panel

Dr. Steven Ferguson, Deputy Director and Chair, Licensing and Entrepreneurship, NCI
Partnering with NCI

Dr. Keith Flaherty, Director of Developmental Therapeutics at the Massachusetts General Hospital Cancer Center and Professor of medicine at Harvard Medical School
Presenting Apricity Health

Dr. Priti Hegde, CSO of Foundation Medicine
The History and Future of Genomic Medicine

Dr. Brian Lelyand Jones, Former Director of Emory and McGill Cancer Centers, CMO National Foundation for Cancer Research, Chief Science Officer, The Darwin Foundation
Topic: TBD

Dr. Jerome Kim, Director-General of the International Vaccine Institute
Looking Beyond COVID-19 Vaccine Phase 3 Trials

Dr. Heidi Larson, Founding Director of the Vaccine Confidence Project at the London School of Hygiene & Tropical Medicine, Former Director of Global Immunisation Communication at UNICEF, Professor of Anthropology, Risk and Decision Science, Author of STUCK: How Vaccine Rumors Start – and Why They Don’t Go Away
Vaccine Hesitancy

Dr. Paul Marik, Chief, Pulmonary and Critical Care Medicine, Eastern Virginia Medical School
Clinical Trial Update on the Use of Ivermectin to Treat COVID-19

Dr. Philip Friedlander, Professor Medicine, Hematology, Dermatology and Medical Oncology, Mt. Sinai
T-Cell Therapy Panel

Dr. Wayne Froland, Former Head of Complex Manufacturing, Merck, Chief Technology and Manufacturing Officer for Swan Bio
T-Cell Therapy Panel

Sung Poblete, CEO, Stand Up 2 Cancer
Women in Cancer Panel

Dr. Greg Simon, Executive Director, Biden Cancer Initiative, Executive Director, White House Cancer, Moonshot Task Force, Chief of Domestic Policy under Vice President Al Gore, Pfizer, Former Director of Worldwide Policy
Update: Biden’s Cancer Policy

Dr. Alfred Slanetz, CEO, Geneius Biotechnology, Former CEO, Bluebird Bio, Former Head of Product Development, Genetech
T-Cell Therapy Panel

Dr. Pam Sharma, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson
Women in Cancer Panel

© 2021 Oncology Investor Conference Series